Retacrit®

Biosimilar medicine authorized by the European Commission

Retacrit®

ACTIVE PRINCIPLE:
Epoetin Zeta

INDICATION:
Anemia secondary to oncological processes
end-stage renal failure

DATE:
18/12/2007

STATUS:
Authorized

MORE INFORMATION

BioSim Newsletter

Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.

SUBSCRIBE